MABIONICS LIMITED

MABIONICS Limited is an early‑stage biotechnology company pioneering the engineering of monoclonal antibodies (mAbs) to open new frontiers in the healthcare sector. Drawing on a leadership team with more than 40 years of cumulative global healthcare experience, the firm has spent a decade developing a proprietary cell‑synthesis platform – MSYNC – and its first candidate drug, MBN‑1. Both are designed to generate a new generation of mAbs with pharmacological profiles that address the limitations of existing biological therapies, targeting high‑impact autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, psoriasis and Crohn’s disease.

Based at North Point Business Park, New Mallow Road, MABIONICS collaborates with a network of world‑class scientific and operational partners to accelerate its research and development pipeline. The company’s ambition is to become a world‑class R&D biotech organisation by 2030, with an estimated valuation of €25‑30 billion. Its core specialisations include mAb engineering, advanced cell‑synthesis technology and the translation of these innovations into therapeutic candidates for patients and the broader biotech industry.